R. Ajer Jeffrey's most recent trade in Viridian Therapeutics Inc was a trade of 21,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | Jeffrey R. Ajer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 21,000 | 21,000 | - | - | Stock Option (Right to Buy) | |
| Viridian Therapeutics Inc | Jeffrey R. Ajer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2025 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | 31 Dec 2024 | 120,000 | 120,000 | - | - | Stock Option | ||
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 82.91 per share. | 02 May 2024 | 5,000 | 66,767 (0%) | 0% | 82.9 | 414,550 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 68.65 per share. | 02 May 2024 | 300 | 71,767 (0%) | 0% | 68.6 | 20,594 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.87 per share. | 15 Mar 2024 | 22,580 | 71,467 (0%) | 0% | 83.9 | 1,893,785 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 87.07 per share. | 05 Mar 2024 | 4,000 | 94,047 (0%) | 0% | 87.1 | 348,280 | Common Stock |
| Biomarin Pharmaceutical In... | R. Ajer Jeffrey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 21,440 | 82,244 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | R. Ajer Jeffrey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 9,338 | 91,582 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Ajer R. Jeffrey | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 6,465 | 98,047 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 16 Aug 2023 | 5,000 | 60,804 (0%) | 0% | 90 | 450,000 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 66.88 per share. | 16 Aug 2023 | 318 | 65,804 (0%) | 0% | 66.9 | 21,267 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 23,070 | 23,070 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 93.41 per share. | 15 Mar 2023 | 20,510 | 65,486 (0%) | 0% | 93.4 | 1,915,839 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 10,110 | 89,967 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.74 per share. | 15 Mar 2023 | 3,971 | 85,996 (0%) | 0% | 87.7 | 348,416 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 20,760 | 61,848 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 10,380 | 72,228 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 7,629 | 79,857 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.81 per share. | 25 Jan 2023 | 49,000 | 90,088 (0%) | 0% | 67.8 | 3,322,690 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2023 | 46,800 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 115.65 per share. | 25 Jan 2023 | 44,825 | 45,263 (0%) | 0% | 115.7 | 5,184,191 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 116.15 per share. | 25 Jan 2023 | 4,175 | 41,088 (0%) | 0% | 116.2 | 484,943 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2023 | 2,200 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 86.12 per share. | 02 Nov 2022 | 3,000 | 41,088 (0%) | 0% | 86.1 | 258,360 | Common Stock |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | Sale of securities on an exchange or to another person at price $ 3.16 per share. | 23 Sep 2022 | 4,198 | 38,512 (0%) | 0% | 3.2 | 13,266 | Common Stock |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 20,400 | 20,400 | - | - | Stock Option | |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 10,200 | 42,710 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 95.62 per share. | 11 Aug 2022 | 3,000 | 44,088 (0%) | 0% | 95.6 | 286,860 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.49 per share. | 03 Jun 2022 | 7,021 | 47,088 (0%) | 0% | 77.5 | 544,057 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 78.94 per share. | 29 Apr 2022 | 1,308 | 54,109 (0%) | 0% | 78.9 | 103,254 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 62.41 per share. | 29 Apr 2022 | 340 | 55,417 (0%) | 0% | 62.4 | 21,218 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 82.47 per share. | 13 Apr 2022 | 1,180 | 55,077 (0%) | 0% | 82.5 | 97,315 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 79.43 per share. | 29 Mar 2022 | 1,618 | 57,638 (0%) | 0% | 79.4 | 128,518 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 79.56 per share. | 29 Mar 2022 | 1,381 | 56,257 (0%) | 0% | 79.6 | 109,872 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 81.78 per share. | 22 Mar 2022 | 6,129 | 59,256 (0%) | 0% | 81.8 | 501,230 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 81.00 per share. | 22 Mar 2022 | 2,073 | 65,385 (0%) | 0% | 81 | 167,913 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 28,670 | 28,670 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 11,940 | 77,163 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.27 per share. | 15 Mar 2022 | 8,418 | 68,745 (0%) | 0% | 78.3 | 658,877 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.72 per share. | 15 Mar 2022 | 1,287 | 67,458 (0%) | 0% | 80.7 | 103,887 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 9,370 | 65,223 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 20,400 | 20,400 | - | - | Stock Option | |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 10,200 | 36,175 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | Sale of securities on an exchange or to another person at price $ 17.78 per share. | 22 Sep 2021 | 3,665 | 32,510 (0%) | 0% | 17.8 | 65,164 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 73.60 per share. | 30 Apr 2021 | 2,739 | 55,853 (0%) | 0% | 73.6 | 201,590 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 62.41 per share. | 30 Apr 2021 | 342 | 58,592 (0%) | 0% | 62.4 | 21,343 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 78.81 per share. | 08 Apr 2021 | 1,537 | 58,250 (0%) | 0% | 78.8 | 121,131 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 74.79 per share. | 30 Mar 2021 | 1,652 | 59,787 (0%) | 0% | 74.8 | 123,553 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 76.30 per share. | 24 Mar 2021 | 1,181 | 61,439 (0%) | 0% | 76.3 | 90,110 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.52 per share. | 22 Mar 2021 | 1,513 | 62,620 (0%) | 0% | 78.5 | 118,801 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 77.99 per share. | 18 Mar 2021 | 1,308 | 64,133 (0%) | 0% | 78.0 | 102,011 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 26,400 | 26,400 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 10,720 | 72,001 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.39 per share. | 15 Mar 2021 | 5,273 | 66,728 (0%) | 0% | 78.4 | 413,350 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.21 per share. | 15 Mar 2021 | 1,287 | 65,441 (0%) | 0% | 77.2 | 99,369 | Common Stock |
| Biomarin Pharmaceutical In... | Jeffrey R. Ajer | EVP, Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 79.91 per share. | 14 Oct 2020 | 2,121 | 61,281 (0%) | 0% | 79.9 | 169,489 | Common Stock |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | Sale of securities on an exchange or to another person at price $ 17.25 per share. | 28 Sep 2020 | 3,250 | 25,975 (0%) | 0% | 17.3 | 56,063 | Common Stock |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2020 | 18,200 | 18,200 | - | - | Stock Option | |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2020 | 9,100 | 29,225 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Jeffrey R. Ajer | Director | Sale of securities on an exchange or to another person at price $ 19.74 per share. | 21 Sep 2020 | 2,250 | 20,125 (0%) | 0% | 19.7 | 44,415 | Common Stock |